Trials / Completed
CompletedNCT01916863
Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™ (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LX4211 400 mg | |
| DRUG | canagliflozin 300 mg | |
| DRUG | LX4211 Placebo |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2013-10-01
- First posted
- 2013-08-06
- Last updated
- 2013-10-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01916863. Inclusion in this directory is not an endorsement.